The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy outcomes in immune checkpoint inhibitor (ICI)-treated metastatic urothelial carcinoma (mUC) patients (pts) requiring treatment interruption (TI) due to immune-related adverse events (irAEs).
 
Amanda Nizam
No Relationships to Disclose
 
Iris Yeong- Fung Sheng
No Relationships to Disclose
 
Kimberly D. Allman
Consulting or Advisory Role - AstraZeneca; Bayer; Exelixis
Speakers' Bureau - Amgen; Exelixis
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Exelixis
 
Allison Martin
No Relationships to Disclose
 
Timothy D. Gilligan
Travel, Accommodations, Expenses - Dendreon
 
Shilpa Gupta
Stock and Other Ownership Interests - Nektar
Honoraria - AstraZeneca; Bristol-Myers Squibb; Exelixis; Janssen Oncology; Merck Sharp & Dohme; Pfizer; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Exelixis; Janssen Oncology
Research Funding - Bristol-Myers Squibb; Merck; Pfizer; Seagen
 
Moshe Chaim Ornstein
Consulting or Advisory Role - Eisai; Exelixis; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Exelixis
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Exelixis